The use of prior authorizations by insurance companies for certain oral cancer drugs can lead to significant delays in patients' obtaining the medication and make it more likely that some would discontinue the drug, according ...
Dec 13, 2023
0
0
Regular leisure time physical activity may reduce the risk of breast cancer for women before menopause, according to new researchers from The Institute of Cancer Research, London.
Dec 12, 2023
0
0
Men with hormone-resistant prostate cancer and specific genetic mutations who were treated with the PARP inhibitor drug olaparib survived longer than men treated with traditional hormone therapy, according to an analysis ...
Dec 7, 2023
0
1
Almost all postmenopausal patients aged 50-–69 years with stage I hormone receptor (HR)-positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease free five years ...
Dec 7, 2023
0
0
A new risk model uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy ...
Dec 6, 2023
0
0
Lidocaine—often used as a numbing agent for outpatient medical procedures—activates certain bitter taste receptors through two unique mechanisms that result in cancer cell death, according to researchers from the Perelman ...
Nov 22, 2023
0
180
A collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the treatment of BRAF mutated low-grade pediatric gliomas.
Nov 21, 2023
0
11
A new familial lung cancer caused by an inherited mutation in EGFR has been described in a study published online Oct. 23 in the Journal of Clinical Oncology.
Nov 19, 2023
0
1
Individuals racialized as Black and newly diagnosed with colorectal cancer (CRC) receive worse and less-timely guideline-concordant care, according to a study published online Nov. 8 in the Journal of Clinical Oncology.
Nov 14, 2023
0
0
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed ...
Nov 3, 2023
0
3
